Project Details
Description
Phase II Study of Pembrolizumab in the Immunoreactive Ovarian Cancer Subtype
Status | Active |
---|---|
Effective start/end date | 3/6/19 → 3/30/26 |
Funding
- UNIVERSITY OF CALIFORNIA, LOS ANGEL
- MERCK
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.